These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36375336)

  • 1. Structural optimization and biological evaluation of 1-adamantylcarbonyl-4-phenylpiperazine derivatives as FXR agonists for NAFLD.
    Qin T; Gao X; Lei L; Zhang W; Feng J; Wang X; Shen Z; Liu Z; Huan Y; Wu S; Xia J; Zhang L
    Eur J Med Chem; 2023 Jan; 245(Pt 1):114903. PubMed ID: 36375336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease.
    Qin T; Gao X; Lei L; Feng J; Zhang W; Hu Y; Shen Z; Liu Z; Huan Y; Wu S; Xia J; Zhang L
    Eur J Med Chem; 2023 Apr; 252():115307. PubMed ID: 37003047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pose Filter-Based Ensemble Learning Enables Discovery of Orally Active, Nonsteroidal Farnesoid X Receptor Agonists.
    Xia J; Wang Z; Huan Y; Xue W; Wang X; Wang Y; Liu Z; Hsieh JH; Zhang L; Wu S; Shen Z; Zhang H; Wang XS
    J Chem Inf Model; 2020 Mar; 60(3):1202-1214. PubMed ID: 32050066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling.
    Gu M; Zhang S; Zhao Y; Huang J; Wang Y; Li Y; Fan S; Yang L; Ji G; Tong Q; Huang C
    Pharmacol Res; 2017 Jul; 121():22-32. PubMed ID: 28428116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altenusin, a Nonsteroidal Microbial Metabolite, Attenuates Nonalcoholic Fatty Liver Disease by Activating the Farnesoid X Receptor.
    Zheng Z; Zhao Z; Li S; Lu X; Jiang M; Lin J; An Y; Xie Y; Xu M; Shen W; Guo GL; Huang Y; Li S; Zhang X; Xie W
    Mol Pharmacol; 2017 Oct; 92(4):425-436. PubMed ID: 28739572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.
    Yao J; Zhou CS; Ma X; Fu BQ; Tao LS; Chen M; Xu YP
    World J Gastroenterol; 2014 Oct; 20(39):14430-41. PubMed ID: 25339829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
    Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y
    J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and structure-activity relationship studies of novel partial FXR agonists for the treatment of fatty liver.
    Qiu Q; Wang W; Zhao X; Chen Y; Zhao S; Zhu J; Xu X; Geng R
    Bioorg Chem; 2020 Nov; 104():104262. PubMed ID: 32919135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INT-767 improves histopathological features in a diet-induced
    Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
    World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR.
    Nie H; Song C; Wang D; Cui S; Ren T; Cao Z; Liu Q; Chen Z; Chen X; Zhou Y
    Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3087-3094. PubMed ID: 28951211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.
    McGettigan BM; McMahan RH; Luo Y; Wang XX; Orlicky DJ; Porsche C; Levi M; Rosen HR
    J Biol Chem; 2016 Oct; 291(44):23058-23067. PubMed ID: 27605663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and Structural Optimization of Dual FXR/PPARĪ“ Activators.
    Schierle S; Neumann S; Heitel P; Willems S; Kaiser A; Pollinger J; Merk D
    J Med Chem; 2020 Aug; 63(15):8369-8379. PubMed ID: 32687365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
    Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
    Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a novel and orally active Farnesoid X receptor agonist for the protection of acetaminophen-induced hepatotoxicity.
    Cai Z; Wang B; Zhou Z; Zhao X; Hu L; Ren Q; Deng L; Li Z; Wang G
    Chem Biol Drug Des; 2022 Mar; 99(3):483-495. PubMed ID: 34936214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Betulinic acid alleviates endoplasmic reticulum stress-mediated nonalcoholic fatty liver disease through activation of farnesoid X receptors in mice.
    Gu M; Zhao P; Zhang S; Fan S; Yang L; Tong Q; Ji G; Huang C
    Br J Pharmacol; 2019 Apr; 176(7):847-863. PubMed ID: 30635917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse.
    Lin C; Yu B; Liu X; Chen L; Zhang Z; Ye W; Zhong H; Bai W; Yang Y; Nie B
    Biomed Pharmacother; 2022 Jun; 150():112984. PubMed ID: 35447541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schaftoside alleviates HFD-induced hepatic lipid accumulation in mice via upregulating farnesoid X receptor.
    Liu M; Zhang G; Wu S; Song M; Wang J; Cai W; Mi S; Liu C
    J Ethnopharmacol; 2020 Jun; 255():112776. PubMed ID: 32205261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
    Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
    Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling.
    Zhai Y; Zhou W; Yan X; Qiao Y; Guan L; Zhang Z; Liu H; Jiang J; Liu J; Peng L
    Phytomedicine; 2022 Dec; 107():154444. PubMed ID: 36155217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.